November 13, 2017
A Federal Circuit panel upheld a lower court ruling that found Apotex Inc. did not infringe a patent covering Amgen Inc.'s blockbuster drug Neulasta, while clarifying the amount of weight courts should put on statements made in the prelitigation process by companies making biosimilars.
October 03, 2017
Federal Circuit judges on Tuesday questioned how much weight courts should put on statements made in the prelitigation process by companies making copycat versions of biologic drugs, as Amgen looks to overturn a ruling that cleared Apotex of infringing a patent related to its blockbuster biologic Neulasta.